MedTrace Logo

Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) for Chronic Insomnia ：A Randomized Controlled Trial

NCT04779372 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2022-12-07

No results posted yet for this study

Summary

This randomized, open, parallel controlled study aims to explore the clinical effectiveness of smartphone-based digital Cognitive behavioural therapy for insomnia（dCBT-I）. Patients who diagnosed chronic insomnia disorder and proficient in using mobile phone intended to receive CBT-I. Participants will be random allocation into Group dCBT-I and Group Sleep Education. Primary outcome is the insomnia severity as measured using the Insomnia Severity Index (ISI).

Conditions

  • Chronic Insomnia

Interventions

BEHAVIORAL

smartphone-based dCBT-I from a Wechat applet

Participants will receive 6-week smartphone-based dCBT-I from a Wechat applet.

BEHAVIORAL

sleep education

Participants will receive sleep education like the advices getting from common sleep clinic.

Sponsors & Collaborators

  • Zeen health (Beijing) Technology Co., Ltd

    collaborator UNKNOWN

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Jing Ma, Doctor · Peking University First Hospital

  • Cheng Zhang, Doctor · Peking University First Hospital

  • Yanan Liu, Doctor · Peking University First Hospital

  • Yane Shen, Postgraduate · Peking University First Hospital

  • Xiaoming Guo, Doctor · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-24
Primary Completion
2022-01-06
Completion
2022-07-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04779372 on ClinicalTrials.gov